CAR-T cell therapy is approved for certain forms of lymphoma, leukemia, and multiple myeloma, usually when previous treatments have not been sufficiently effective or the disease has recurred. The European approval for each of these therapies specifies exactly which forms and stages of the disease are eligible.

Starting in the fall of 2026, the center will offer gene therapy for severe forms of these congenital red blood cell disorders. The contact person is Dr. Laura Distelmaier of the Department of Medicine III.

For some autoimmune diseases—such as those treated in rheumatology and neurology—cell and immunotherapies are currently being tested in clinical trials. We will discuss with your treating physician whether you are eligible for a trial.